- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00245141
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma
Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vincristine, dactinomycin, and cyclophosphamide together with or without radiation therapy works in treating patients with embryonal rhabdomyosarcoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the progression-free survival rate in patients with low-risk embryonal rhadomyosarcoma treated with a shortened treatment schedule of vincristine, dactinomycin, and cyclophosphamide with or without radiotherapy.
OUTLINE: Patients receive vincristine IV, dactinomycin IV, and cyclophosphamide IV. Patients may also undergo radiotherapy. Treatment repeats every 3 weeks for up to 8 courses (total of 24 weeks) in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Fukushima, Japan, 960-1295
- Recruiting
- Fukushima Medical University Hospital
-
Gifu, Japan, 500-8705
- Recruiting
- Gifu University Graduate School of Medicine
-
Hiroshima, Japan, 734-8551
- Recruiting
- Hiroshima University Hospital
-
Kagoshima, Japan, 890-8520
- Recruiting
- Kagoshima University
-
Kyoto, Japan, 606-8507
- Recruiting
- Kyoto University Hospital
-
Kyoto, Japan, 602-8566
- Recruiting
- Kyoto Prefectural University of Medicine
-
Osaka, Japan, 545-8586
- Recruiting
- Osaka City University
-
Osaka, Japan, 558-0056
- Recruiting
- Osaka General Medical Center
-
Saitama, Japan, 339-8551
- Recruiting
- Saitama Children's Medical Center
-
Sapporo, Japan, 006-0041
- Recruiting
- Hokkaido Medical Center for Child Health and Rehabilitation
-
Tokyo, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
Tokyo, Japan, 160-8582
- Recruiting
- Keio University School of Medicine
-
Tokyo, Japan, 104
- Recruiting
- St. Luke's International Hospital
-
Tokyo, Japan, 113-8510
- Recruiting
- Tokyo Medical and Dental University
-
Tokyo, Japan, 143-8541
- Recruiting
- Toho University School of Medicine
-
Tokyo, Japan, 173
- Recruiting
- Nihon University Itabashi Hospital
-
Toyama, Japan, 930-0194
- Recruiting
- Toyama University Hospital
-
Contact:
- Hirokazu Kanegane
- Phone Number: 81-76-434-7313
- Email: kanegane@ms.toyama-mpu.ac.jp
-
Yamagata, Japan, 990-9585
- Recruiting
- Yamagata University Hospital
-
-
Aichi
-
Anjo, Aichi, Japan, 446-8602
- Recruiting
- Anjo Kosei Hosptial
-
Nagakuti, Aichi, Japan, 480-1103
- Recruiting
- Aichi Medical University
-
Nagoya, Aichi, Japan, 460-0001
- Recruiting
- National Hospital Orgnization Nagoya Medical Center
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 790-0024
- Recruiting
- Ehime Prefectural Central Hospital
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 811-1395
- Recruiting
- National Kyushu Cancer Center
-
Kurume City, Fukuoka, Japan, 830-0011
- Recruiting
- Kurume University School of Medicine
-
-
Gifu
-
Gifu-shi, Gifu, Japan, 500-8513
- Recruiting
- Gifu Municipal Hospital
-
-
Gunma
-
Seta-gun, Gunma, Japan, 377-8577
- Recruiting
- Gunma Children's Medical Center
-
-
Hiroshima
-
Kure, Hiroshima, Japan, 737-0023
- Recruiting
- National Hospital Organization - Medical Center of Kure
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8556
- Recruiting
- Sapporo Medical University
-
Sapporo, Hokkaido, Japan, 060-8638
- Recruiting
- Hokkaido University Graduate School of Medicine
-
-
Hyogo
-
Kobe, Hyogo, Japan, 650
- Recruiting
- Kobe City General Hospital
-
-
Ibaraki
-
Mito-shi, Ibaraki, Japan, 311-4145
- Recruiting
- Ibaraki Children's Hospital
-
Tsukuba-city, Ibaraki, Japan, 305-8575
- Recruiting
- University of Tsukuba
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8641
- Recruiting
- Kanazawa Medical University
-
Kanazawa-shi, Ishikawa, Japan, 920-02
- Recruiting
- Ishikawa Prefectural Central Hospital
-
-
Kagoshima
-
Kagoshima City, Kagoshima, Japan, 892-8580
- Recruiting
- Kagoshima City Hospital
-
-
Kanagawa
-
Tokyo, Kanagawa, Japan, 157-8535
- Recruiting
- National Center for Child Health and Development
-
Yokohama, Kanagawa, Japan, 236-0004
- Recruiting
- Yokohama City University
-
Yokohama-shi, Kanagawa, Japan, 227-8502
- Recruiting
- Showa University Fujigaoka Hospital
-
-
Miyazaki
-
Miyazaki-gun, Miyazaki, Japan, 889-1692
- Recruiting
- Miyazaki Medical College University of Miyazaki
-
-
Nagano
-
Toyoshina-machi, Nagano, Japan, 399-8288
- Recruiting
- Nagano Children's Hospital
-
-
Osaka
-
Izumi, Osaka, Japan, 594-1101
- Recruiting
- Osaka Medical Center and Research Institute for Maternal and Child Health
-
Suita-shi, Osaka, Japan, 565-0871
- Recruiting
- Osaka City General Hospital
-
Suita-shi, Osaka, Japan, 565-0871
- Recruiting
- Osaka University Graduate School of Medicine
-
Takatsuki City, Osaka, Japan, 569-8686
- Recruiting
- Osaka Medical College
-
-
Saitama
-
Koshigaya, Saitama, Japan, 343-8555
- Recruiting
- Dokkyo University School of Medicine
-
Tokorozawa, Saitama, Japan, 359-8513
- Recruiting
- National Defense Medical College
-
-
Shiga
-
Otsu-shi, Shiga, Japan, 520-21
- Recruiting
- Shiga University of Medical Science
-
-
Shimane
-
Izumo, Shimane, Japan, 693-8501
- Recruiting
- Shimane University Hospital
-
Izumo, Shimane, Japan, 693-0068
- Recruiting
- Shimane Prefectural Central Hospital
-
Contact:
- Ken Taketani, MD
- Phone Number: 81-853-20-2219
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japan, 430-8558
- Recruiting
- Seirei Hamamatsu General Hospital
-
-
Tokyo
-
Kiyosei, Tokyo, Japan, 204-8567
- Recruiting
- Tokyo Metropolitan Kiyose Children's Hospital
-
Contact:
- Takashi Kaneko, MD
- Phone Number: 81-424-91-0011
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of embryonal rhabdomyosarcoma
- Primary operation for pathological diagnosis within the past 42 days
The following variants are eligible:
- Botryoid
- Spindle cell
- Anaplastic
Meets 1 of the following stage criteria:
Stage I, clinical group I or II (N0), defined by all of the following criteria:
- Favorable site, including orbit, head, and neck (excluding parameningeal sites), genitourinary region (excluding bladder/prostate sites), or biliary tract
- Tumor any size
- Completely resected disease OR microscopic residual disease
- Lymph nodes clinically negative
Stage I, clinical group III (N0), defined by all of the following criteria:
- Favorable site
- Tumor any size
- Gross residual disease allowed (orbit only)
- Lymph nodes clinically negative
Stage II, clinical group I (N0, Nx), defined by all of the following criteria:
- Unfavorable site (any sites not listed as favorable sites)
- Tumor ≤ 5 cm in diameter
- Completely resected disease
- Lymph nodes clinically negative OR lymph node involvement unknown
PATIENT CHARACTERISTICS:
Performance status
- 0-3
Life expectancy
- Not specified
Hematopoietic
- WBC ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 7.5 g/dL
Hepatic
- SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 2.5 times ULN
- Bile acid ≤ 2.5 times ULN
Renal
Creatinine based on age as follows:
- < 0.8 mg/dL (for patients < 5 years of age)
- < 1.2 mg/dL (for patients 5-9 years of age)
- < 1.5 mg/dL (for patients ≥ 10 years of age)
Cardiovascular
- No severe heart disease
Other
- Not pregnant or nursing
- Must have acceptable organ function for age
- No uncontrolled infection
- No other active malignancy
- No other treated malignancy within the past 5 years
- No hypersensitivity to study drugs
- No Charcot-Marie-Tooth disease
- No chickenpox
PRIOR CONCURRENT THERAPY:
Chemotherapy
- No prior anticancer chemotherapy
Endocrine therapy
- Prior anticancer steroids allowed
Radiotherapy
- No prior radiotherapy
Other
- No concurrent pentostatin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Disease-free survival as measured by Kaplan-Meier method 3 years after study entry
|
Secondary Outcome Measures
Outcome Measure |
---|
Overall survival as measured by Kaplan-Meier method 3 years after study entry
|
Progression-free survival as measured by Kaplan-Meier method during events
|
Complete response rate (orbit, group III only) at completion of study treatment
|
Rate of toxicity as measured by NCI-CTC v 2.0 3 years after study entry
|
Collaborators and Investigators
Investigators
- Masa-aki Kumagai, MD, National Center for Child Health and Development
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Neoplasms, Muscle Tissue
- Myosarcoma
- Rhabdomyosarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Vincristine
- Dactinomycin
Other Study ID Numbers
- JRSG-UHA-PED03-01
- CDR0000453316 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted